A Phase 3 interventional study of CRE8 sirolimus-eluting stent and RESOLUTE zotarolimus-eluting stent in Coronary Artery Disease, sponsored by CID S.p.A.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-03-25.
Sponsored by CID S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.
Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 134th largest by planned enrollment of the 324 interventional ones that give a count, is one of 14 that started in 2014, is one of 16 in phase 3, and was the 106th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:
Nanjing First Hospital, Nanjing Medical University · Sites in China
Ages 18–80
BrosMed Medical Co., Ltd · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
Beijing Inno Medicine Co., Ltd. · Sites in China, United States, Australia and 1 more country
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
543 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 25 · Phase 3 24 · Phase 4 66
First in 2000; this study’s year is marked. 14 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 430 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 307 across the 324 interventional studies, 720 across the 218 observational. Of the 187 that completed or were terminated, 24 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 543 have an industry lead sponsor. The 10 most frequent:
CID S.p.A. is the lead sponsor of 7 studies on the registry; none are open to participants now.
CID S.p.A. has 2 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
32 of the studies in Coronary Artery Disease with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05175274Phase 3Qingdao Central HospitalColchicine Use for Primary Prevention of Coronary Artery Disease | 2027-03-01 |
| NCT07439133Phase 3Sinotau Pharmaceutical GroupComparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR) | 2027-06 |
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
| NCT06845410Peking Union Medical College HospitalClinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study | 2026-12 |
| NCT06917664China National Center for Cardiovascular DiseasesTreatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease | 2026-12 |
Add all 32 to your calendar (.ics) → With an account.
Among the 543 studies in Coronary Artery Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, efficacy and deliverability of the CRE8 sirolimus-eluting stent and the RESOLUTE zotarolimus-eluting stent in the treatment of patients with de novo coronary artery lesions.
This study consists of a randomized controlled cohort and a long stent observational cohort. The randomized controlled trial is a prospective, multi-center, non-inferior, randomized controlled trial. The control device (RESOLUTE zotarolimus-eluting stent) used in this trial was provided by Medtronic. RESOLUTE zotarolimus-eluting stent has been already approved by China Food and Drug Administration (CFDA) in 2009 and become commercially available in Chinese market. 400 patients enrolled in this trial will be randomly assigned to CRE8 group (n=200) and RESOLUTE group (n=200) in a 1:1 ratio. The long stent observational trial plans to enroll 30 consecutive patients. Patients in the observational cohort will receive the long CRE8 stent with length 38mm.All 430 patients will be required to receive clinical follow-up at 1 month, 6 months, 9 months, 12 months and annually up to 5 years after the procedure, and angiographic follow-up at 9 months after the procedure. The primary endpoint is in-stent LLL at 9 months after the procedure, and the secondary endpoints are device success rate, device-oriented cardiovascular composite endpoint, patient-oriented cardiovascular composite endpoint and stent thrombosis.
Inclusion Criteria:
Inclusion criteria for randomized cohort:
Inclusion criteria for the long stent observational cohort:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CRE8 sirolimus-eluting stent system
Device: CRE8 sirolimus-eluting stent
RESOLUTE zotarolimus-eluting stent system
Device: RESOLUTE zotarolimus-eluting stent
The CRE8 stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium alloy and is coated with i-carbofilm.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
The RESOLUTE stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium tungsten alloy. It has been approved by CFDA in 2009 and commercially available in Chinese market
In-stent late lumen loss (LLL)
Time frame: 9months after the procedure
In-stent, proximal stent edge, distal stent edge and In-segment binary restenosis rate
Time frame: 9months after the procedure
In-segment late lumen loss (LLL)
Time frame: 9months after the procedure
Target lesion failure (TLF) rate
Time frame: 1month, 6months, 9months, 12months and annually up to 5 years follow-up
Number of participants with stent thrombosis per ARC definition
Time frame: 1month, 6months, 9months, 12months and annually up to 5 years follow-up
The patient-oriented composite endpoint includes all-cause death, all MIs, or any revascularizations
Time frame: 1month, 6months, 9months, 12months and annually up to 5 years follow-up
device and lesion success rates
Time frame: immediately after the procedure
clinical success rate
Time frame: 7 days after the procedure
The record gives a start of Nov 2014, a primary completion of Oct 2016 and a completion of Apr 2021. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CID S.p.A.